Cargando…

Minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the SCAN‐B initiative

BACKGROUND: Selection of systemic therapy for primary breast cancer is currently based on clinical biomarkers along with stage. Novel genomic tests are continuously being introduced as more precise tools for guidance of therapy, although they are often developed for specific patient subgroups. The S...

Descripción completa

Detalles Bibliográficos
Autores principales: Rydén, L., Loman, N., Larsson, C., Hegardt, C., Vallon‐Christersson, J., Malmberg, M., Lindman, H., Ehinger, A., Saal, L. H., Borg, Å.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817401/
https://www.ncbi.nlm.nih.gov/pubmed/29341157
http://dx.doi.org/10.1002/bjs.10741
_version_ 1783300871475429376
author Rydén, L.
Loman, N.
Larsson, C.
Hegardt, C.
Vallon‐Christersson, J.
Malmberg, M.
Lindman, H.
Ehinger, A.
Saal, L. H.
Borg, Å.
author_facet Rydén, L.
Loman, N.
Larsson, C.
Hegardt, C.
Vallon‐Christersson, J.
Malmberg, M.
Lindman, H.
Ehinger, A.
Saal, L. H.
Borg, Å.
author_sort Rydén, L.
collection PubMed
description BACKGROUND: Selection of systemic therapy for primary breast cancer is currently based on clinical biomarkers along with stage. Novel genomic tests are continuously being introduced as more precise tools for guidance of therapy, although they are often developed for specific patient subgroups. The Sweden Cancerome Analysis Network – Breast (SCAN‐B) initiative aims to include all patients with breast cancer for tumour genomic analysis, and to deliver molecular subtype and mutational data back to the treating physician. METHODS: An infrastructure for collection of blood and fresh tumour tissue from all patients newly diagnosed with breast cancer was set up in 2010, initially including seven hospitals within the southern Sweden regional catchment area, which has 1.8 million inhabitants. Inclusion of patients was implemented into routine clinical care, with collection of tumour tissue at local pathology departments for transport to the central laboratory, where routines for rapid sample processing, RNA sequencing and biomarker reporting were developed. RESULTS: More than 10 000 patients from nine hospitals have currently consented to inclusion in SCAN‐B with high (90 per cent) inclusion rates from both university and secondary hospitals. Tumour samples and successful RNA sequencing are being obtained from more than 70 per cent of patients, showing excellent representation compared with the national quality registry as a truly population‐based cohort. Molecular biomarker reports can be delivered to multidisciplinary conferences within 1 week. CONCLUSION: Population‐based collection of fresh tumour tissue is feasible given a decisive joint effort between academia and collaborative healthcare groups, and with governmental support. An infrastructure for genomic analysis and prompt data output paves the way for novel systemic therapy for patients from all hospitals, irrespective of size and location.
format Online
Article
Text
id pubmed-5817401
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons, Ltd.
record_format MEDLINE/PubMed
spelling pubmed-58174012018-02-26 Minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the SCAN‐B initiative Rydén, L. Loman, N. Larsson, C. Hegardt, C. Vallon‐Christersson, J. Malmberg, M. Lindman, H. Ehinger, A. Saal, L. H. Borg, Å. Br J Surg Original Articles BACKGROUND: Selection of systemic therapy for primary breast cancer is currently based on clinical biomarkers along with stage. Novel genomic tests are continuously being introduced as more precise tools for guidance of therapy, although they are often developed for specific patient subgroups. The Sweden Cancerome Analysis Network – Breast (SCAN‐B) initiative aims to include all patients with breast cancer for tumour genomic analysis, and to deliver molecular subtype and mutational data back to the treating physician. METHODS: An infrastructure for collection of blood and fresh tumour tissue from all patients newly diagnosed with breast cancer was set up in 2010, initially including seven hospitals within the southern Sweden regional catchment area, which has 1.8 million inhabitants. Inclusion of patients was implemented into routine clinical care, with collection of tumour tissue at local pathology departments for transport to the central laboratory, where routines for rapid sample processing, RNA sequencing and biomarker reporting were developed. RESULTS: More than 10 000 patients from nine hospitals have currently consented to inclusion in SCAN‐B with high (90 per cent) inclusion rates from both university and secondary hospitals. Tumour samples and successful RNA sequencing are being obtained from more than 70 per cent of patients, showing excellent representation compared with the national quality registry as a truly population‐based cohort. Molecular biomarker reports can be delivered to multidisciplinary conferences within 1 week. CONCLUSION: Population‐based collection of fresh tumour tissue is feasible given a decisive joint effort between academia and collaborative healthcare groups, and with governmental support. An infrastructure for genomic analysis and prompt data output paves the way for novel systemic therapy for patients from all hospitals, irrespective of size and location. John Wiley & Sons, Ltd. 2018-01-17 2018-01 /pmc/articles/PMC5817401/ /pubmed/29341157 http://dx.doi.org/10.1002/bjs.10741 Text en © 2018 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Rydén, L.
Loman, N.
Larsson, C.
Hegardt, C.
Vallon‐Christersson, J.
Malmberg, M.
Lindman, H.
Ehinger, A.
Saal, L. H.
Borg, Å.
Minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the SCAN‐B initiative
title Minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the SCAN‐B initiative
title_full Minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the SCAN‐B initiative
title_fullStr Minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the SCAN‐B initiative
title_full_unstemmed Minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the SCAN‐B initiative
title_short Minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the SCAN‐B initiative
title_sort minimizing inequality in access to precision medicine in breast cancer by real‐time population‐based molecular analysis in the scan‐b initiative
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817401/
https://www.ncbi.nlm.nih.gov/pubmed/29341157
http://dx.doi.org/10.1002/bjs.10741
work_keys_str_mv AT rydenl minimizinginequalityinaccesstoprecisionmedicineinbreastcancerbyrealtimepopulationbasedmolecularanalysisinthescanbinitiative
AT lomann minimizinginequalityinaccesstoprecisionmedicineinbreastcancerbyrealtimepopulationbasedmolecularanalysisinthescanbinitiative
AT larssonc minimizinginequalityinaccesstoprecisionmedicineinbreastcancerbyrealtimepopulationbasedmolecularanalysisinthescanbinitiative
AT hegardtc minimizinginequalityinaccesstoprecisionmedicineinbreastcancerbyrealtimepopulationbasedmolecularanalysisinthescanbinitiative
AT vallonchristerssonj minimizinginequalityinaccesstoprecisionmedicineinbreastcancerbyrealtimepopulationbasedmolecularanalysisinthescanbinitiative
AT malmbergm minimizinginequalityinaccesstoprecisionmedicineinbreastcancerbyrealtimepopulationbasedmolecularanalysisinthescanbinitiative
AT lindmanh minimizinginequalityinaccesstoprecisionmedicineinbreastcancerbyrealtimepopulationbasedmolecularanalysisinthescanbinitiative
AT ehingera minimizinginequalityinaccesstoprecisionmedicineinbreastcancerbyrealtimepopulationbasedmolecularanalysisinthescanbinitiative
AT saallh minimizinginequalityinaccesstoprecisionmedicineinbreastcancerbyrealtimepopulationbasedmolecularanalysisinthescanbinitiative
AT borga minimizinginequalityinaccesstoprecisionmedicineinbreastcancerbyrealtimepopulationbasedmolecularanalysisinthescanbinitiative